ASPIC

German Cancer Research Center (DKFZ), Heidelberg, Germany

11 - 13 May, 2017

See more informations here: http://www.dkfz.de/en/ecec2017/index.html

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

05 May, 2017

See more informations here: http://www.cambridge-pcc.org/upcoming_events.html

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

05 May, 2017

See more informations here: http://www.cambridge-pcc.org/upcoming_events.html

CNIO Auditorium, Madrid, Spain

02 - 04 May, 2017

See more informations here: http://www.cnio.es/eventos/index.asp?ev=1

CNIO Auditorium, Madrid, Spain

02 - 04 May, 2017

See more informations here: http://www.cnio.es/eventos/index.asp?ev=1

Li Ka Shing Centre, Cambridge, United Kingdom

27 - 28 April, 2017

See more informations here: http://www.cancerresearchuk.org/funding-for-researchers/research-events-and-conferences/international-oesophageal-cancer-symposium-2017

Li Ka Shing Centre, Cambridge, United Kingdom

27 - 28 April, 2017

See more informations here: http://www.cancerresearchuk.org/funding-for-researchers/research-events-and-conferences/international-oesophageal-cancer-symposium-2017

Hotel SB Diagonal Zero Barcelona, Barcelona, Spain

22 April, 2017

See more informations here: http://www.primeoncology.org/live-education/heme/expert-practice-cll-2017/

Hotel SB Diagonal Zero Barcelona, Barcelona, Spain

22 April, 2017

See more informations here: http://www.primeoncology.org/live-education/heme/expert-practice-cll-2017/

O grupo de Epigenética & Biologia do Cancro do Centro de Investigação juntamente com os Serviços de Epidemiologia e Urologia do IPO do Porto e em colaboração com colegas do grupo de Epigenética e Biologia do Cancro do Instituto de Investigação Biomédica de Bellvitge, em Barcelona, Espanha, demonstraram recentemente  num estudo publicado na revista Molecular Cancer, que a metilação aberrante do promotor de alguns microRNAs pode constituir biomarcador de diagnóstico e prognóstico para cancro da Próstata (CaP).